rethinkPeptides Search
Menu
Study breakdown

Tirzepatide Real-World Efficacy in Heart Failure With Preserved Ejection Fraction

evidence
The takeaway

Real-world analysis confirms tirzepatide efficacy in HFpEF patients, validating clinical trial results in everyday clinical practice.

Key finding

Real-world analysis confirms tirzepatide efficacy in HFpEF patients, validating clinical trial resul

What the researchers found

Real-world analysis confirms tirzepatide efficacy in HFpEF patients, validating clinical trial results in everyday clinical practice.

Why it matters

Relevant to peptide therapeutics.

How the study worked

In publication.

What this study cannot tell us

In publication.

How to read the evidence

Based on design.

When this study was published

Published in 2025.

The bigger picture

Advances peptide evidence.

Questions still open

  • Long-term implications?
  • Evidence comparison?
  • Next steps?

Common questions

What does this mean?
Real-world analysis confirms tirzepatide efficacy in HFpEF patients, validating clinical trial results in everyday clinical practice.
How reliable?
Consult publication.

Read the original research

Real-world efficacy of tirzepatide in patients with heart failure without diabetes.

Current problems in cardiology, 50(4), 102998

Citation

Augusto, Silvio Nunes; Kaelber, David; Tang, W H Wilson. (2025). Real-world efficacy of tirzepatide in patients with heart failure without diabetes.. Current problems in cardiology, 50(4), 102998. https://doi.org/10.1016/j.cpcardiol.2025.102998